Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-963272 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BMS-963272 or Placebo once daily (QD) | EXPERIMENTAL | - |
| BMS-963272 or Placebo every 12 hours (Q12H) | EXPERIMENTAL | - |
| BMS-963272 or Placebo every 8 hours (Q8H) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-963272 | DRUG | Single dose with varying frequency among groups |
| Placebo | DRUG | Specified dose on specified days |
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Participants must be in good general health, in the opinion of the investigator, with no clinically significant deviation from normal in medical history, phy...
BMS-963272 is an investigational small molecule developed by Bristol-Myers Squibb for metabolic research. It was studied in obese but otherwise healthy adult participants. The compound has been evaluated in a single Phase 1 clinical trial, which is now completed.
BMS-963272 was studied in obese but otherwise healthy adult participants, a metabolic research setting. It is an investigational agent and is not an approved treatment. Its only recorded clinical trial enrolled 36 participants and has been completed.
Bristol-Myers Squibb Company, which trades under the ticker BMY, is the developer of BMS-963272. The company sponsored the Phase 1 study of the compound in obese but otherwise healthy adults.
BMS-963272 is in Phase 1 development. It is an investigational small molecule and has not been approved for any indication. One Phase 1 trial has been completed, and no active trials are currently listed.
BMS-963272 was evaluated in one clinical trial, NCT04116632, titled A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy Adults. The Phase 1 trial enrolled 36 participants in the United States and is completed.
NCT04116632 was a Phase 1 multiple dose study of BMS-963272 in obese but otherwise healthy adults. It was randomized, double blind, and controlled, enrolling 36 participants aged 18 years and older in the United States. The trial is completed.